Recently, a study suggested that serotonin receptor inverse agonists of 5-HT2A, such as pimavanserin, might have therapeutic benefits in the treatment of psychosis in AD patients [55], without negative effects on cognition and with no effect on dopamine receptors. Here, HTR2A is linked to Alzheimer disease.